Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.

by Marine Sivignon, Rémi Monnier, Bertrand Tehard, Stéphane Roze
Published 2020-01-01

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

by Audrey Petitjean, Jayne Smith-Palmer, William Valentine, Bertrand Tehard, Stephané Roze
Published 2019-02-01